Undisclosed tau antibody therapeutic / ProMIS Neurosci - LARVOL DELTA

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting (GlobeNewswire) - "ProMIS Neurosciences Inc...today announced that the Company will present preclinical data on computationally-derived vaccines for neurodegenerative diseases at the American Academy of Neurology (AAN) Annual Meeting taking place from April 5-9, 2025 in San Diego...Results from the preclinical study showed that immunization with a single conformational epitope, peptide 301, the target of PMN310 antibody, was sufficient to produce maximal reactivity against AD brain oligomers...Results from the preclinical study showed that vaccination with conformational B cell epitopes produced high affinity antibodies with the desired selectivity for pathogenic ASyn and identified optimal vaccine configurations for further development."

Preclinical • Alzheimer's Disease • CNS Disorders • Dementia